ClinicalTrials.gg
CompletedNCT03178851Updated Nov 19, 2021Results posted

Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma

A Phase 1 interventional study of Atezolizumab and Cobimetinib in Malignant Melanoma, sponsored by Hoffmann-La Roche. Completed at 43 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-11-19.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
155
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing atezolizumab in Melanoma — 3 open to participants now, 7 under way, 1 of them phase 3. atezolizumab · Melanoma.

Enrollment
5th of 17
155 · median 67
Started
2017
with 3 others
Phase 1
4 of 17
1 open now
Registered
6th of 17
by date
Lead sponsor
5 of 17
Hoffmann-La Roche

Among the 17 studies testing atezolizumab in Melanoma, this one is the 5th largest by enrollment, is one of 4 that started in 2017, is one of 4 in phase 1, and was the 6th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

3 of the 17 studies testing atezolizumab in Melanoma are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About atezolizumab

atezolizumab: first FDA approval 2016 (TECENTRIQ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing atezolizumab in Melanoma, or all of them as a file.
02

Study summary

This study will evaluate the preliminary efficacy, safety, and pharmacokinetics of cobimetinib and atezolizumab in participants with advanced BRAF V600-wild type (WT), metastatic, or unresectable locally advanced melanoma who have progressed on prior anti-PD-1 therapy. In addition, this study will evaluate the efficacy, safety, and pharmacokinetics of atezolizumab monotherapy in participants with BRAFV600-WT metastatic or unresectable locally advanced melanoma, who have not been previously treated.

03

Conditions studied

  • Malignant Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Disease-Specific Inclusion Criteria: Cohorts A and B:

  • confirmed Stage IV () or unresectable Stage IIIc BRAF V600 WT (locally advanced) melanoma
  • Documentation of BRAF V600 mutation-negative status in melanoma tumor tissue (archival [\< 5 years old] or newly obtained) through use of a clinical mutation test approved by the local health authority
  • according to (RECIST) v1.1
  • Disease progression on or after treatment with a programmed death (PD)-1 inhibitor either as monotherapy or in combination with other agent(s)

Additional Disease-Specific Inclusion Criteria in Cohort B ( Cohort):

  • Progressed on or after therapy within 12 weeks before study start
  • Received a minimum of two cycles of anti-PD-1 therapy
  • Meet the following criteria for resistance to an anti-PD-1 agent: primary resistance defined as disease progression, according to RECIST v1.1, as best response; secondary resistance defined as disease progression after initial confirmed response according to RECIST v1.1
  • Consent to undergo tumor biopsies of accessible lesions, before and during treatment and at radiographic progression, for biomarker analyses.
  • Have at least two accessible lesions that are amenable to excisional or core-needle (minimum three cores and minimum diameter 18 gauge; however, 16 gauge is desirable) biopsy without unacceptable risk of a major procedural complication. Exceptions may be made if patient has only one lesion that allows multiple biopsies.

Disease-Specific Inclusion Criteria: Cohort C:

  • Histologically confirmed Stage IV (metastatic) or unresectable Stage IIIc BRAFV600-WT (locally advanced) melanoma
  • Naive to prior systemic anti-cancer therapy for melanoma
  • Documentation of BRAFV600 mutation-negative status in melanoma tumor tissue (archival [\< 5 years old] or newly obtained) through use of a clinical mutation test approved by the local health authority
  • A representative, formalin-fixed, paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or 20 slides containing unstained, freshly cut, serial sections must be submitted along with an associated pathology report prior to study entry.
  • Measurable disease according to RECIST v1.1.

General Inclusion Criteria:

  • Ability to comply with the study protocol, in the investigator's judgment
  • (ECOG) Performance Status of 0 or 1
  • Available and adequate baseline tumor tissue sample
  • ≥ 18 weeks
  • Adequate hematologic and end-organ function, defined by laboratory test results, obtained within 14 days before initiation of study treatment
  • For women of : abstinent or use an effective form of method for at least 3 months for cobimetinib and at least 5 months for atezolizumab. Women must refrain from donating eggs during this same period.
  • For men: abstinent or use contraceptive measures and agreement to refrain from donating sperm for at least 3 months after cobimetinib and atezolizumab

Exclusion criteria

Exclusion criteria

  • Prior treatment with a mitogen activated-protein kinase (MAPK) inhibitor
  • Ocular melanoma
  • Major surgical procedure other than for diagnosis within 4 weeks before initiation of study treatment, or anticipation of need for a major surgical procedure during the course of the study
  • Traumatic injury within 2 weeks before initiation of study treatment
  • Palliative radiotherapy within 14 days before initiation of study treatment
  • Active (other than BRAF V600 mutation-negative melanoma) or malignancy within 3 years
  • Treatment with any anti-cancer agent 14 days prior to Cycle, Day 1 other than aPD-1 based therapy
  • Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1. Clinically stable patients with manageable immune-related adverse events resulting from prior cancer immunotherapy may be eligible for the study.
  • For Cohort C only: any prior anti-cancer therapy for advanced melanoma
  • History or evidence of ongoing serous retinopathy or retinal vein occlusion (RVO) at baseline
  • History of cardiac dysfunction
  • Active or untreated central nervous system (CNS)
  • History of metastases to brain stem, midbrain, pons, or medulla, or within 10 millimeter (mm) of the optic apparatus (optic nerves and chiasm)
  • History of metastatic disease
  • (HIV) infection
  • Active tuberculosis
  • Severe infection within 4 weeks before initiation of study treatment
  • Signs or symptoms of infection within 2 weeks before initiation of study treatment
  • Treatment with oral or intravenous (IV) antibiotics within 2 weeks prior to Day 1 of Cycle 1
  • Active or chronic viral or C infection
  • Active or history of disease or immune deficiency
  • Prior allogeneic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • Treatment with systemic medications with the following exceptions:
  • Patients who have received acute, low-dose systemic immunosuppressant medication (≤ 10 mg/day oral prednisone or equivalent) or a one-time pulse dose of systemic immunosuppressant medication (e.g., 48 hours of for a contrast allergy) are eligible for the study after Medical Monitor approval has been obtained.
  • Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids for (COPD) or asthma, or low-dose corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible for the study.
  • Current severe, uncontrolled systemic disease other than cancer
  • Any Grade >/=3 hemorrhage or bleeding event within 28 days of Day 1 of Cycle 1
  • History of stroke, reversible ischemic neurological defect, or within 6 months prior to Day 1
  • Anticipated use of any concomitant medication during or within 7 days before initiation of study treatment that is known to cause
  • Any psychological, familial, sociological, or geographic condition that may hamper compliance with the protocol and follow-up after treatment discontinuation
  • History of malabsorption or other clinically significant metabolic dysfunction that may interfere with absorption of oral study treatment
  • Pregnant or breastfeeding, or intending to become pregnant during the study
  • Known clinically significant liver disease
  • Any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding that contraindicates the use of an drug, may affect the interpretation of the results, or may render the participant at high risk for treatment complications
  • Treatment with a live, attenuated vaccine within 4 weeks before initiation of study treatment, or anticipation of need for such a vaccine during the course of the study
  • Known to any component of the atezolizumab or cobimetinib formulations
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Treatment with any other investigational agent or participation in another clinical study with therapeutic intent
  • Inability or unwillingness to swallow pills
  • Requirement for concomitant therapy or food that is prohibited during the study
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
155 participants (actual)

Study arms

  • Experimental
    Cohort A

    Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib and atezolizumab treatment during 28-day cycles.

    Biological: Atezolizumab · Drug: Cobimetinib

  • Experimental
    Cohort B

    Participants with disease progression on or after treatment with an anti-PD-1 agent will receive cobimetinib prior to initiating atezolizumab treatment during Cycle 1. During subsequent 28-day cycles participants will initiate both atezolizumab and cobimetinib on Day 1 of each cycle. Participants in this cohort will undergo tumor biopsies before and during treatment.

    Drug: Cobimetinib · Biological: Atezolizumab

  • Experimental
    Cohort C

    Participants with advanced melanoma, who have not received previous treatment, will receive atezolizumab monotherapy during 21-day cycles.

    Biological: Atezolizumab

Interventions

  • BiologicalAtezolizumab

    Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit

    Also known as: Tecentriq

  • Cobimetinib, 60 mg orally once daily (QD) on Days 1-21 of each 28-day cycle, until loss of clinical benefit

    Also known as: Cotellic

  • BiologicalAtezolizumab

    Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit

    Also known as: Tecentriq

  • BiologicalAtezolizumab

    Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit

    Also known as: Tecentriq

06

What researchers measure

Primary outcomes

  1. Investigator-Assessed Objective Response Rate (ORR)

    ORR is defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to approximately 2 years

  2. Investigator-Assessed Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.

    Time frame: Week 16

Secondary outcomes

  1. Investigator-Assessed Duration of Response (DOR)

    DOR is defined as the time from the first occurrence of documented OR to disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Up to approximately 2 years

  2. Overall Survival (OS)

    OS is defined as the time from Cycle 1, Day 1 to death from any cause.

    Time frame: Up to approximately 2 years

  3. Investigator-Assessed Progression-Free Survival (PFS)

    PFS is defined as the time from Cycle 1, Day 1 to the first occurrence of disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Up to approximately 2 years

  4. Serum Concentration of Atezolizumab

    Time frame: Cycle 1, Day 15; Day 1 of Cycles 2, 3, 4, 8

  5. Plasma Concentration of Cobimetinib

    Time frame: Cycle 1, Day 15

  6. Percentage of Participants With Adverse Events

    An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

    Time frame: Baseline through follow up

  7. Change From Baseline in Percentage of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab

    To evaluate the immune response to atezolizumab the percentage of participants with ADAs to atezolizumab will be determined at baseline and during the study.

    Time frame: Cycle 1 Day 1 pre-dose to 120 days after the last dose of study medication

  8. Cohort C: Independent-Review-Committee-Assessed (IRC) ORR

    ORR is defined as the percentage of participants with confirmed objective response (OR), as determined by an independent review committee (IRC) according to RECIST v1.1. Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by an independent review committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

    Time frame: Approximately 2 years for Cohorts A and B and 19 months for Cohort C

  9. Cohort C: IRC-Assessed DCR

    DCR is defined as the percentage of participants with CR, PR, or stable disease (SD), as determined by an independent review committee (IRC) according to RECIST v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.

    Time frame: Approximately 21 months

  10. Cohort C: IRC-Assessed DOR

    DOR is defined as the time from the first occurrence of documented OR to disease progression, as determined by an independent review committee (IRC) according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Approximately 21 months

  11. Cohort C: IRC-Assessed PFS

    PFS is defined as the time from Cycle 1, Day 1 to the first occurrence of disease progression, as determined by an independent review committee (IRC) according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

    Time frame: Approximately 21 months

07

Results

Posted Jun 12, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort ACohort BCohort C
Started921152
Completed000
Not completed921152
Withdrew: Death48225
Withdrew: Withdrawal by subject800
Withdrew: Lost to follow-up520
Withdrew: Adverse event001
Withdrew: Study termination by sponsor31726

Outcome measures

PrimaryInvestigator-Assessed Objective Response Rate (ORR)

ORR is defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to approximately 2 years
Reported as:
Number · Percentage of Participants
Investigator-Assessed Objective Response Rate (ORR)
Percentage of ParticipantsCohort ACohort BCohort C
Investigator-Assessed Objective Response Rate (ORR)12.0 (6.12 to 20.39)36.4 (10.93 to 69.21)38.5 (25.30 to 52.98)
PrimaryInvestigator-Assessed Disease Control Rate (DCR)

DCR is defined as the percentage of participants with CR, PR, or stable disease (SD) at 16 weeks. Per RECIST v1.1, CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.

Time frame:
Week 16
Reported as:
Number · Percentage of Participants
Investigator-Assessed Disease Control Rate (DCR)
Percentage of ParticipantsCohort ACohort BCohort C
Investigator-Assessed Disease Control Rate (DCR)37.0 (27.12 to 47.66)54.5 (23.38 to 83.25)46.2 (32.23 to 60.53)
SecondaryInvestigator-Assessed Duration of Response (DOR)

DOR is defined as the time from the first occurrence of documented OR to disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Up to approximately 2 years
Reported as:
Median · Months
Investigator-Assessed Duration of Response (DOR)
MonthsCohort ACohort BCohort C
Investigator-Assessed Duration of Response (DOR)24.2 (7.4 to 24.2)NA (7.8 to NA)NA (20.1 to NA)
SecondaryOverall Survival (OS)

OS is defined as the time from Cycle 1, Day 1 to death from any cause.

Time frame:
Up to approximately 2 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsCohort ACohort BCohort C
Overall Survival (OS)12.5 (9.4 to 16.7)NA (NA to NA)22.0 (11.7 to NA)
SecondaryInvestigator-Assessed Progression-Free Survival (PFS)

PFS is defined as the time from Cycle 1, Day 1 to the first occurrence of disease progression, as determined by the investigator according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Up to approximately 2 years
Reported as:
Median · Months
Investigator-Assessed Progression-Free Survival (PFS)
MonthsCohort ACohort BCohort C
Investigator-Assessed Progression-Free Survival (PFS)3.7 (3.5 to 5.6)9.3 (1.8 to 20.1)3.7 (2.1 to 7.4)
SecondarySerum Concentration of Atezolizumab
Time frame:
Cycle 1, Day 15; Day 1 of Cycles 2, 3, 4, 8
Reported as:
Geometric mean · ug/mL
Serum Concentration of Atezolizumab
ug/mLCohort ACohort BCohort C
Cmax - Cycle 1 Day 15271 ± 22.1275 ± 21.9388 ± 20.5
Cmin - Cycle 2 Day 165.3 ± 33032.9 ± 154073.2 ± 55.0
Cmin - Cycle 3 Day 192.4 ± 44237.6 ± 7490113 ± 47.8
Cmin - Cycle 4 Day 1121 ± 23783.7 ± 844128 ± 50.8
Cmin - Cycle 8 Day 1210 ± 46.8NA ± NA159 ± 58.7
SecondaryPlasma Concentration of Cobimetinib
Time frame:
Cycle 1, Day 15
Reported as:
Geometric mean · ug/mL
Plasma Concentration of Cobimetinib
ug/mLCohort ACohort B
Cycle 1 Day 15 - Ctrough165 ± 137125 ± 86.6
Cycle 1 Day 15 - Css318 ± 75.2208 ± 59.6
SecondaryPercentage of Participants With Adverse Events

An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.

Time frame:
Baseline through follow up
Reported as:
Number · Percentage of Participants
Percentage of Participants With Adverse Events
Percentage of ParticipantsCohort ACohort BCohort C
Percentage of Participants With Adverse Events98.9100100
SecondaryChange From Baseline in Percentage of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab

To evaluate the immune response to atezolizumab the percentage of participants with ADAs to atezolizumab will be determined at baseline and during the study.

Time frame:
Cycle 1 Day 1 pre-dose to 120 days after the last dose of study medication
Reported as:
Number · Percentage of Participants
Change From Baseline in Percentage of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab
Percentage of ParticipantsCohort ACohort BCohort C
Change From Baseline in Percentage of Participants With Anti-drug Antibodies (ADAs) to Atezolizumab32.530.010.0
SecondaryCohort C: Independent-Review-Committee-Assessed (IRC) ORR

ORR is defined as the percentage of participants with confirmed objective response (OR), as determined by an independent review committee (IRC) according to RECIST v1.1. Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by an independent review committee (IRC) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.

Time frame:
Approximately 2 years for Cohorts A and B and 19 months for Cohort C
Reported as:
Number · Percentage of Participants
Cohort C: Independent-Review-Committee-Assessed (IRC) ORR
Percentage of ParticipantsCohort C
Cohort C: Independent-Review-Committee-Assessed (IRC) ORR27.3 (14.96 to 42.79)
SecondaryCohort C: IRC-Assessed DCR

DCR is defined as the percentage of participants with CR, PR, or stable disease (SD), as determined by an independent review committee (IRC) according to RECIST v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters. SD is defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for disease progression, taking as reference the smallest sum on study. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline, or the appearance of one or more new lesions.

Time frame:
Approximately 21 months
Reported as:
Number · Percentage of Participants
Cohort C: IRC-Assessed DCR
Percentage of ParticipantsCohort C
Cohort C: IRC-Assessed DCR38.6 (24.36 to 54.50)
SecondaryCohort C: IRC-Assessed DOR

DOR is defined as the time from the first occurrence of documented OR to disease progression, as determined by an independent review committee (IRC) according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Approximately 21 months
Reported as:
Median · Months
Cohort C: IRC-Assessed DOR
MonthsCohort C
Cohort C: IRC-Assessed DORNA (NA to NA)
SecondaryCohort C: IRC-Assessed PFS

PFS is defined as the time from Cycle 1, Day 1 to the first occurrence of disease progression, as determined by an independent review committee (IRC) according to RECIST v1.1, or death from any cause, whichever occurs first. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.

Time frame:
Approximately 21 months
Reported as:
Median · Months
Cohort C: IRC-Assessed PFS
MonthsCohort C
Cohort C: IRC-Assessed PFS3.7 (2.1 to 11.7)

Adverse events

Collected over Baseline through follow up. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A48/92 (52.2%)42/92 (45.7%)90/92 (97.8%)
Cohort B2/11 (18.2%)5/11 (45.5%)11/11 (100%)
Cohort C25/52 (48.1%)15/52 (28.8%)50/52 (96.2%)
Most frequent serious events
Showing 10 of 65
Most frequent serious events
EventCohort ACohort BCohort C
Adrenal insufficiencyEndocrine disorders0/921/110/52
MeningitisInfections and infestations0/921/110/52
FractureInjury, poisoning and procedural complications0/921/110/52
Acute kidney injuryRenal and urinary disorders1/921/110/52
DyspnoeaRespiratory, thoracic and mediastinal disorders1/921/111/52
Acute coronary syndromeCardiac disorders0/921/110/52
Chest painGeneral disorders0/921/110/52
AngiogramInvestigations0/921/110/52
DiarrhoeaGastrointestinal disorders4/920/111/52
PyrexiaGeneral disorders4/920/112/52
Most frequent other events
Showing 10 of 124
Most frequent other events
EventCohort ACohort BCohort C
DiarrhoeaGastrointestinal disorders65/9210/119/52
FatigueGeneral disorders42/927/115/52
Dermatitis acneiformSkin and subcutaneous tissue disorders49/927/110/52
NauseaGastrointestinal disorders48/924/117/52
RashSkin and subcutaneous tissue disorders31/925/116/52
PyrexiaGeneral disorders37/921/113/52
VomitingGastrointestinal disorders35/923/117/52
ConstipationGastrointestinal disorders27/924/119/52
Alanine aminotransferase increasedInvestigations7/924/115/52
Aspartate aminotrasferase increasedInvestigations10/924/116/52

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Cohort ACohort BCohort CTotal
Mean60.7 ± 11.862.3 ± 9.661.2 ± 11.861.0 ± 11.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort BCohort CTotal
Female3331753
Male59835102
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
Hispanic or Latino612532
Not Hispanic or Latino821026118
Unknown or Not Reported4015
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort ACohort BCohort CTotal
American Indian or Alaska Native0022
Asian2002
Native Hawaiian or Other Pacific Islander0000
Black or African American1045
White881146145
More than one race0000
Unknown or Not Reported1001
08

Study locations

43 sites
  • HonorHealth Research Institute - Bisgrove
    Scottsdale, Arizona 85258, United States
  • University of Colorado Hospital - Anschutz Cancer Pavilion
    Aurora, Colorado 80045, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Sarah Cannon Research Institute
    Nashville, Tennessee 37203, United States
  • Baylor University Medical Center
    Dallas, Texas 75231, United States
  • Blacktown Hospital
    Blacktown, New South Wales 2148, Australia
  • Melanoma Institute Australia
    North Sydney, New South Wales 2060, Australia
  • Mid North Coast Cancer Institute
    Port Macquarie, New South Wales 2444, Australia
  • Greenslopes Private Hospital; Clinic Pharmacy
    Greenslopes, Queensland 4120, Australia
  • Flinders Medical Centre
    Bedford Park, South Australia 5042, Australia
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • University Clinical Centre of the Republic of Srpska
    Banja Luka, 78000, Bosnia and Herzegovina
  • University Clinic Ctr Sarajevo
    Sarajevo, 71 000, Bosnia and Herzegovina
  • Instituto de Ensino e Pesquisa Clinica do Ceara
    Fortaleza, CE 60130-241, Brazil
  • Cenantron - Centro Avancado de Tratamento Oncologico
    Belo Horizonte, MG 30130-090, Brazil
  • Instituto Nacional de Cancer - INCa; Oncologia
    Rio de Janeiro, RJ 20560-120, Brazil
  • Hospital Sao Vicente de Paulo
    Passo Fundo, RS 99010-090, Brazil
  • Hospital das Clinicas - UFRGS
    Porto Alegre, RS 90035-903, Brazil
  • Hospital Sao Lucas - PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Hospital Amaral Carvalho
    Jau, SP 17210-120, Brazil
  • Cape Town Oncology Trials
    Cape Town, 7570, South Africa
  • GVI Constantiaberg
    Cape Town, 7800, South Africa
  • Johese Clinical Research
    Centurion, 1692, South Africa
  • Cancercare
    George, 6529, South Africa
  • Wits Clinical Research; Charlotte Maxeke Johannesburg Academic Hospital
    Johannesburg, 2193, South Africa
  • Cancercare
    Port Elizabeth, 6045, South Africa
  • Steve Biko Academic Hospital; Oncology
    Pretoria, 0002, South Africa
  • Hospital Clinico Universitario de Santiago
    Santiago de Compostela, LA Coruña 15706, Spain
  • Clínica Universidad de Navarra
    Pamplona, Navarra 31620, Spain
  • Hospital Universitario Virgen Macarena
    Seville, Sevilla 41071, Spain
  • Hospital Universitari Quiron Dexeus
    Barcelona, 08028, Spain
  • Hospital Clinic I Provincial
    Barcelona, 08036, Spain
  • MD Anderson Cancer Center
    Madrid, 28033, Spain
  • Hospital Universitario Ramón y Cajal; Pharmacy
    Madrid, 28034, Spain
  • Hospital Universitario 12 de Octubre; Servicio de Oncologia
    Madrid, 28041, Spain
  • Hospital Universitario La Paz; Servicio de Oncologia
    Madrid, 28046, Spain
  • Central Municipal Hospital - Uzhgorod State University
    Uzhgorod, Chernihiv Governorate 88017, Ukraine
  • Public Institution: City Multispecialty Clinical Hospital #4 under Dnipropetrovsk Regional Council
    Dnipropetrovsk, 49102, Ukraine
  • National Cancer Institute MOH of Ukraine
    Kiev, 36022, Ukraine
  • Lviv State Oncology Regional Treatment and Diagnostic Centre
    Lviv, 79031, Ukraine
  • Sumy Regional Clinical Onc Ctr
    Sumy, 40005, Ukraine
09

References and documents

Publications

  • Barteselli G, Goodman GR, Patel Y, Caro I, Xue C, McCallum S. Characterization of Serous Retinopathy Associated with Cobimetinib: Integrated Safety Analysis of Four Studies. Drug Saf. 2022 Dec;45(12):1491-1499. doi: 10.1007/s40264-022-01248-2. Epub 2022 Oct 30. PubMed 36310331 ↗
  • de Azevedo SJ, de Melo AC, Roberts L, Caro I, Xue C, Wainstein A. First-line atezolizumab monotherapy in patients with advanced BRAFV600 wild-type melanoma. Pigment Cell Melanoma Res. 2021 Sep;34(5):973-977. doi: 10.1111/pcmr.12960. Epub 2021 Feb 15. PubMed 33476492 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2017 to primary completion in May 2019, 23 months.

Results were first posted in Jun 2020, 1 year after primary completion.

Of 225 industry-sponsored phase 1 interventional studies under Melanoma, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 66. This study's 23 months is below that.

Counting every sponsor, half of 411 studies reached it within 49 months; a quarter within 31 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2017
First posted
Jun 7, 2017
StartActual
Jun 20, 2017
Primary completionActual
May 29, 2019
CompletionActual
Sep 21, 2020
Results first posted
Jun 12, 2020
Last update
Nov 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03178851
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 7, 2017
Start date
Jun 20, 2017
Primary completion
May 29, 2019
Completion
Sep 21, 2020
Results posted
Jun 12, 2020
Last update
Nov 19, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Atezolizumab · Cobimetinib

Start the discussion